A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia

Trial Profile

A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Oct 2016 Results of retrospective analysis of pooled data of this and other two trials (NCT01559272, NCT01515423) to characterize the population pharmacokinetics of paliperidone published in the Clinical Pharmacokinetics
    • 15 Jul 2016 Planned locations also included Brazil, Bulgaria, Russia and South Africa.
    • 27 Jun 2016 Results published in Janssen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top